A biopharmaceutical company that develops experimental drugs for autoimmune and rare diseases through a family of nimble subsidiaries it calls 'Vants' — including Immunovant, Priovant, and Pulmovant — each focused on a specific drug candidate. Founded in 2014 by entrepreneur Vivek Ramaswamy, the name blends 'ROI' (return on investment) with the '-vant' suffix stamped on every subsidiary. Its most advanced candidate, brepocitinib, is under FDA review for the rare muscle disease dermatomyositis.
Operating income swung to a $415M gain on a litigation settlement, while R&D spend rose 32% ahead of an FDA decision on brepocitinib.
A $771M litigation settlement gain turned the quarter profitable. fell 33.5% to $1.4M and the operating loss before the gain deepened to $366.0M as R&D spending rose 32% to $202.0M, driven by the anti-FcRn franchise and mosliciguat. The company enters the brepocitinib FDA decision with $3.8B in cash, excluding the settlement proceeds received in July.
Key takeaways
was $415.2M, compared with a $284.9M loss a year earlier, driven entirely by a $770.2M gain recognized from Genevant's expected portion of a $950M patent infringement settlement with Moderna.
fell 33.5% to $1.4M, down from $2.2M, as the company has generated no product sales since the October 2024 Dermavant divestiture removed VTAMA.
R&D expenses rose 32% to $202.0M, with $44.8M of the increase coming from higher anti-FcRn franchise costs and $4.7M from mosliciguat as both programs advanced through clinical trials.
Section summaries
Management's Discussion and Analysis
R&D spend rose 32% YoY to $202M driven by anti-FcRn and mosliciguat progression; $3.8B cash pre-Moderna payment supports runway.
⌄
Total fell to $1.4M from $2.2M, while operating expenses grew 28% to $367.8M, deepening the operating loss to $366.0M.
R&D expense increased $49.1M to $202.0M, led by $44.8M higher anti-FcRn franchise costs and $4.7M higher mosliciguat costs as programs advanced.
G&A expenses rose 23% to $165.5M, primarily from $18.8M in employee bonuses tied to the Moderna settlement and $6.3M in employer payroll taxes on equity awards.
Cash, equivalents, and marketable securities totaled $3.8B at quarter-end, down from $4.5B a year earlier, with $208.7M used to 7.3M shares during the quarter.
The company received the $771.6M Genevant settlement payment from Moderna in July 2026, after the quarter closed, with an additional of up to $1.3B dependent on a Federal Circuit appeal ruling expected in 2027.
What changed
The prior quarter flagged whether license and milestone could grow from $2.0M: it fell to $1.4M, the lowest quarterly revenue in the series, as Genevant license income continued to decline.
The batoclimab Phase 3 myasthenia gravis data readout, previously a binary catalyst, was resolved in FY2025 when the company discontinued batoclimab after the trial failed its primary endpoint, shifting focus to the next-generation candidate IMVT-1402.
The Moderna patent appeal outcome, previously flagged as determining an additional $1.3B , remains unresolved with a Federal Circuit ruling now expected in 2027.
The pace of share repurchases accelerated: $208.7M was deployed this quarter against $318.1M for all of FY2025, with $681.7M remaining under the current $1.0B authorization.
What to watch
FDA decision on brepocitinib for dermatomyositis in Q3 2026, which would define Roivant's first potential commercial launch since the Dermavant sale.
Topline Phase 2 data for mosliciguat in pulmonary hypertension associated with interstitial lung disease, expected in the second half of 2026.
Resolution of the HanAll dispute over batoclimab discontinuation, which could threaten Immunovant's rights to the next-generation asset IMVT-1402.
Federal Circuit appeal ruling on the Moderna patent case, expected in 2027, which determines whether Roivant receives an additional of up to $1.3B.
G&A expense rose $31.5M to $165.5M, mainly from $18.8M in employee bonuses tied to the Moderna settlement and $6.3M in employer payroll taxes on equity awards.
Cash, equivalents, and marketable securities stood at $3.8B as of June 30, 2026, excluding the $771.6M Genevant received from Moderna in July 2026.
The company repurchased 7.3M shares for $208.7M during the quarter, with $681.7M remaining under the current $1.0B authorization.
Key upcoming catalysts include an FDA decision on brepocitinib for dermatomyositis in Q3 2026 and Phase 2 topline data for mosliciguat in PH-ILD in H2 2026.
Quantitative and Qualitative Disclosures About Market Risk
Market risk from interest rates, FX, and equity prices is not material; a 10% adverse move in equity investments would impact fair value by ~$44.5M.
⌄
Cash, equivalents, and marketable securities totaled ~$3.8B ($3.9B with restricted cash) as of June 30, 2026, invested in high-credit-quality, short-duration instruments.
A hypothetical 10% change in interest rates would not materially affect the company’s financial condition or condensed consolidated financial statements.
Operations and expenses are primarily U.S.-dollar-denominated, so foreign currency exposure is not currently significant.
A hypothetical 10% change in foreign exchange rates would not have a material effect on the financial statements.
Equity price risk is concentrated in fair-value investments in Arbutus and Datavant, with changes in recognized in earnings.
A hypothetical 10% increase or decrease in the of the Arbutus and Datavant investments would change their fair value by approximately $44.5 million.
From time to time, we may become involved in legal or regulatory proceedings arising in the ordinary course of our business. We do not currently, however, expect such legal proceedings to have a material adverse effect on our business, operating results or financial condition. H…
⌄
From time to time, we may become involved in legal or regulatory proceedings arising in the ordinary course of our business. We do not currently, however, expect such legal proceedings to have a material adverse effect on our business, operating results or financial condition. However, depending on the nature and timing of a given dispute, an unfavorable resolution could materially affect our current or future results of operations or cash flows.
Clinical trial delays and IP litigation outcomes remain the dominant risks; a new $1.3B contingent payment from Moderna is highlighted.
⌄
Clinical trials face extensive, costly delays from enrollment issues, regulatory disagreements, and safety signals, which could halt development or deny approval.
Interim or topline trial data may materially change upon full audit, and regulatory agencies may reject post-hoc endpoint or statistical changes, jeopardizing approvals.
A $950M Moderna settlement was received, but an additional $1.3B contingent payment depends entirely on a Federal Circuit appeal ruling expected in 2027, with risk of full forfeiture or repayment.
The ongoing Pfizer/BioNTech patent infringement lawsuits remain unresolved, and an adverse ruling could invalidate key patents, narrow protection, or result in costly counterclaims.
Pre-acquisition development problems with in-licensed product candidates could cause unforeseen delays or increased costs, harming future .